Regulatory and quality expertise strengthens Board as Candel advances toward planned Biologics License Application (BLA) submission and potential commercial readiness
Exhibit 99.1 Tipping the balance in favor of the immune system to fight cancer NASDAQ: CADL Corporate Presentation | September 2026 © © 2026 2026 by by C Ca an ndel del T Ther hera ap peu eut ti ic cs s
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.